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Very low-density lipoprotein stimulates the expression of
monocyte chemoattractant protein-1 in mesangial cells
EDWARD G. LYNN, YAW L. SIOW, and KARMIN O
Department of Pharmacology, Faculty of Medicine, University of Hong Kong, Hong Kong, China
Very low-density lipoprotein stimulates the expression of mono- glomerulosclerosis, such as hemodynamic alterations,
cyte chemoattractant protein-1 in mesangial cells. hypertension, hyperlipidemia, coagulation factors, or ge-
Background. Elevated plasma levels of very low-density li- netic factors [2–5]. Plasma lipoproteins play an importantpoprotein (VLDL) are associated with an increased risk for
role in the progression of focal glomerulosclerosis [6, 7].focal glomerulosclerosis, which is analogous to atherosclerosis.
Lipid-induced progressive glomerulosclerosis exhibitsOne feature of focal glomerulosclerosis is the presence of foam
cells derived from the infiltration of circulating monocytes. many histologic similarities to atherosclerosis, such as
Mesangial cells are able to express monocyte chemoattractant lipid deposition, mesangial cell proliferation, foam cell
protein-1 (MCP-1). In this study, the ability of VLDL to stimu- formation, and extracellular matrix expansion [8, 9].late MCP-1 expression in mesangial cells and consequent mono-
It is well known that hyperlipidemia plays an impor-cyte adhesion was investigated.
tant role in the development of atherosclerosis [10]. Re-Methods. For adhesion studies, mesangial cells isolated from
Sprague-Dawley rats were treated with VLDL for six hours, cently, more attention has been paid to the atherogenic
followed by a one-hour incubation with Tamm-Horsfall pro- effect of very low-density lipoproteins (VLDLs), which
tein-1 (THP-1) cells. Mesangial MCP-1 mRNA levels were
are triglyceride-rich lipoproteins. The Lipid Researchdetermined by reverse transcription-polymerase chain reaction.
Clinics Follow-up Study examined the 12-year incidenceMCP-1 protein was determined by solid-phase immunoassay.
Results. VLDL (100 to 300 mg/mL) significantly enhanced of death from coronary heart disease in 10 North Ameri-
the expression and secretion of MCP-1 (54 to 285 ng/well) in can populations and demonstrated that increased plasma
mesangial cells. Such an effect was accompanied by the increased levels of triglycerides were associated with the risk of
adhesion of monocytes to mesangial cells and later the forma-
coronary artery disease death in men [with LDL choles-tion of foam cells from monocytes after ingesting excessive
terol less than 4.1 mmol/L or with high-density lipopro-amounts of VLDL lipids. VLDL-induced MCP-1 expression
and monocyte adhesion were blocked by a protein kinase C tein (HDL) cholesterol less than 0.9 mmol/L] [11]. Other
inhibitor (staurosporine), as well as a calcium channel blocker studies, including the Cholesterol Lowering Atheroscle-
(diltiazem). rosis Study (CLAS) and the Monitored AtherosclerosisConclusions. Our results demonstrate that elevated levels
Regression Study (MARS), have demonstrated that tri-of VLDL, through the action of MCP-1, may contribute to the
glyceride-rich lipoproteins may be significantly related toinfiltration of monocytes into the mesangium and subsequent
foam cell formation. Hence, VLDLs may play a role in the the progression of atherosclerosis, independent of HDL
pathogenesis of focal glomerulosclerosis. One of the mecha- cholesterol levels [12–16]. The similarities in the develop-
nisms of such effect may be mediated through the calcium- ment of atherosclerosis and glomerulosclerosis suggestdependent protein kinase C pathway.
that VLDL may also be involved in the pathogenesis of
renal disease. The elevation of plasma VLDL levels is
frequently seen in patients with nephrotic syndrome andFocal glomerulosclerosis, defined as the presence of
heavy proteinuria [17]. Two lines of evidence suggestsclerotic lesions in glomeruli in a renal biopsy, is an impor-
that VLDL may contribute to the pathogenesis of focaltant cause of nephrotic syndrome and renal failure [1].
glomerulosclerosis. First, glomerular lipid depositionMany factors are involved in the pathogenesis of focal
coupled with infiltration of monocytes/macrophages into
the mesangium was observed in patients with elevated
levels of plasma VLDL [18–21]. Second, it was shownKey words: monocyte chemoattractant protein-1, cytokines, lipopro-
teins, foam cells, focal glomerulosclerosis. in vitro that b-VLDL was able to induce foam cell forma-
tion in macrophages [22], as well as in mesangial cellsReceived for publication March 24, 1999
[23, 24]. These results suggest that VLDL may play anand in revised form September 29, 1999
Accepted for publication November 2, 1999 important role in recruiting monocytes and in the subse-
quent foam cell formation in affected glomeruli, bothÓ 2000 by the International Society of Nephrology
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of which are key events in the pathogenesis of focal VLDL stimulates the expression of MCP-1 in rat mesan-
gial cells, which in turn promotes THP-1 adhesion toglomerulosclerosis.
One important early event in focal glomerulosclerosis mesangial cells. The increase in MCP-1 mRNA levels
induced by VLDL is calcium dependent. We have furtheris the infiltration of monocytes into glomeruli [8, 9, 18, 20],
where they can uptake excess lipids and become foam observed that upon their adhesion to mesangial cells,
attached THP-1 monocytic cells can uptake VLDL lipidscells [22, 25]. The infiltration of monocytes can be in-
duced by chemotactic factors produced in mesangial cells and become foam cells. VLDL can also induce lipid
accumulation in mesangial cells. However, VLDL treat-[26]. Mesangial cells can express a wide variety of growth
factors and cytokines, including monocyte chemoattrac- ment did not seem to affect the protein levels of either
VCAM-1 or ICAM-1 in mesangial cells. Our results sug-tant protein-1 (MCP-1) [27, 28]. MCP-1, a 76 amino acid
peptide, has potent chemotactic activity for monocytes gest that VLDL-induced MCP-1 production in mesangial
cells may contribute to the increased infiltration of[29, 30]. It has been implicated as an important factor
mediating monocyte infiltration in atherosclerotic lesions, monocytes into glomeruli, where they can uptake excess
lipids to form foam cells in the glomerulosclerotic lesion.as well as in glomerulosclerotic lesions [31–33]. MCP-1
mRNA expression levels were shown to be elevated in
rabbit peritoneal macrophages treated with oxidized
METHODS
(ox)LDL and oxVLDL [34], in human vascular endothe-
Isolation and culture of mesangial cellslial cells and smooth muscle cells treated with VLDL
[35], and in human mesangial cells exposed to high glu- Mesangial cells were isolated from the glomeruli of
male Sprague-Dawley rats using a differential sievingcose concentrations [36] in vitro. Increased MCP-1 ex-
pression has also been observed in rat models of tubulo- technique as previously described [42]. Briefly, cortices
were removed and minced before passage through ainterstitial nephritis and crescentic glomerulonephritis
[37, 38]. Biologically active MCP-1 was detected in the series of steel sieves with decreasing pore sizes (200, 150,
and 75 mm). Isolated glomeruli were then digested withurine of patients with inflammatory glomerulopathies
[39]. These elevations in MCP-1 expression may facilitate trypsin and collagenase. Mesangial cells were cultured in
RPMI-1640 medium containing 20% fetal bovine serummonocyte infiltration. However, the role of lipoproteins,
especially VLDL, in recruiting monocytes into the mes- (FBS) supplemented with insulin (5 mg/mL), transferrin
(5 mg/mL), and selenium (95 ng/mL; Sigma Chemicalangium remains to be clarified.
In addition to MCP-1, mesangial cells have been shown Co., St. Louis, MO, USA). Antibiotics (100 U/mL peni-
cillin, 10 mg/mL streptomycin, and 20 mg/mL neomycin)to be able to synthesize cell adhesion molecules, such as
vascular cell adhesion molecule-1 (VCAM-1) and inter- were included in the culture medium (Life Technologies,
Gaithersburg, MD, USA). Cells were subcultured at one-cellular adhesion molecule-1 (ICAM-1) [40]. LDL was
shown to induce VCAM-1 protein expression in both to two-week intervals. Cells between passages 6 through
12 were used for experiments. RPMI-1640 medium con-human and pig aortic endothelial cells [41]. It has also
been reported that mildly oxidized LDL can stimulate taining 0.5% lipoprotein-depleted FBS and antibiotics
were used for experiments. Cells were characterized,both VCAM-1 and ICAM-1 protein expression in human
mesangial cells [40]. However, the possible involvement and the homogeneity of mesangial cells was assessed
by immunofluorescent staining and their resistance toof VLDL in this process has yet to be described.
Many factors have been reported to be able to contrib- puromycin aminonucleoside, as described previously [42].
In brief, immunofluorescent staining was negative forute to the pathogenesis of focal glomerulosclerosis.
These factors include hemodynamic alterations, hyper- cytokeratin and positive for both vimentin and smooth
muscle cell-specific actin. Unlike fibroblasts, mesangialtension, coagulation factors, genetic factors, and hyper-
lipidemia [2–5]. These risk factors are often interrelated cells were resistant to the epithelial cytotoxin puromycin
aminonucleoside (100 mg/mL). The procedure for usingand can act synergistically. Although the pathogenic
mechanisms by which hyperlipidemia leads to focal glo- laboratory animals was approved by the University Ethi-
cal Review Committee.merulosclerosis have not been fully elucidated, the depo-
sition of lipids, proliferation of mesangial cells, infiltra- Horsfall protein-1 (THP-1) cells, a human monocyte
line, were purchased from the American Type Culturetion of monocytes/macrophages, and accumulation of
extracellular matrix in glomeruli have been hypothesized Collection (ATCC, Rockville, MD, USA). Cells were
cultured in RPMI-1640 medium containing 10% FBSto contribute to the pathogenesis of lipid-induced focal
glomerulosclerosis. In the present study, we examined and antibiotics (100 U/mL penicillin, 10 mg/mL strepto-
mycin, and 20 mg/mL neomycin).the role of VLDL in the development of focal glomerulo-
sclerosis by investigating its effect on the expression of Co-cultured mesangial cells and THP-1 cells were
identified by morphology (large, spindle shaped and small,MCP-1 in mesangial cells and consequent THP-1 mono-
cytic cell adhesion. Our results clearly demonstrate that spherical, respectively), as well as by staining with hema-
Lynn et al: VLDL stimulates MCP-1 expression1474
toxylin. Hematoxylin-stained nuclei of mesangial cells say. After incubation of mesangial cells with various
amounts of VLDL, aliquots of culture media and purifiedwere light blue, while THP-1 nuclei were dark blue/black.
MCP-1 protein (Calbiochem, La Jolla, CA, USA) were
Preparation of lipoproteins and liposomes applied to nitrocellulose membrane (0.2 mmol/L) in a
Blood was collected from normal volunteers after a Bio-Dot SF microfiltration apparatus (Bio-Rad, Her-
12-hour fasting, and plasma was prepared by low-speed cules, CA, USA). The membrane was blocked with 5%
centrifugation (1200 3 g, 20 min). Lipoproteins were nonfat milk in phosphate-buffered saline (PBS) for one
prepared by sequential ultracentrifugation as previously hour and then probed with polyclonal anti–MCP-1 anti-
described [43]. Briefly, different lipoproteins were iso- bodies (Pepro Tech EC Ltd., London, UK). Blots were
lated by preparative ultracentrifugation based on their developed using horseradish peroxidase-conjugated sec-
densities: d , 1.006 g/mL for VLDL, 1.019 , d , 1.063 ondary antibodies. Bands were visualized using enzyme
g/mL for LDL, and 1.063 , d , 1.21 g/mL for HDL. chemiluminescence (ECL) reagents (Amersham, Buck-
All lipoprotein preparations were dialyzed extensively inghamshire, UK) and analyzed with a gel documenta-
at 48C against 0.01 mol/L Tris-HCl (pH 7.4) containing tion system (Bio-Rad Gel Doc1000 and Multi-Analystt,
0.15 mol/L NaCl and 0.005 mol/L ethylenediaminetetra- version 1.1).
acetic acid (EDTA). The procedure was approved by
Analysis of monocyte chemoattractant protein-1the University Ethical Review Committee.
mRNA levels in mesangial cellsVery low density lipoprotein-like liposomes were pre-
pared using rapid ethanol injection [42, 44]. The content, Total RNA from cultured cells was isolated with TRIzol
Reagent, as described by the manufacturer (Life Tech-as well as the composition of triglyceride, phospholipid,
and free cholesterol in liposomes, was similar to that nologies). Reverse transcription-polymerase chain reac-
tion (RT-PCR) was performed with 1 mg total RNA infound in VLDL (55:18:7, wt/wt, respectively). In brief,
the lipids were dried using nitrogen stream and then a total volume of 20 mL [6 mmol/L MgCl2, 10 mmol/L
dithiothreitol (DTT), 10 ng/mL polydT, 1 U/mL M-MLVresuspended in 250 mL absolute ethanol. The lipids were
then rapidly injected into 50 mL Hank’s buffered saline reverse transcriptase]. The nucleotide sequences of the
primers used in the PCR reactions were derived fromsolution (HBSS; Life Technologies) while vortexing. Li-
posomes were concentrated to 5 mL using an Amicon rat spleen cells [30]. The MCP-1 sense primer (59-ATC
ACC AGC AGC AGG TGT CCC AAA GAA GCT-39)concentration cell with a YM 100 membrane (Amicon
Inc., Beverly, MA, USA). The liposome concentration and antisense primer (59-AGA AGT GCT TGA GGT
GGT TGT GGA AAA GAG-39) were synthesized bywas determined by assaying the free cholesterol content
of the preparation. Life Technologies. The reaction mixture for PCR con-
tained 10 mmol/L Tris-HCl, 5 mmol/L MgCl2, 1 mmol/L
Determination of THP-1 monocytic cell adhesion to dNTP, 0.4 mmol/L 59 primer, 0.4 mmol/L 39 primer, 2 U
mesangial cells Taq DNA polymerase, and 1 mg cDNA product from
Tamm-Horsfall protein-1 (THP-1) monocytic cells the reverse transcription reaction. After an initial dena-
were used as a source of monocyte-like cells. Mesangial turation for five minutes at 958C, 30 cycles of PCR ampli-
cells were cultured for 6 to 24 hours in 35 mm dishes fication (958C for 1 min, 558C for 1 min, and 728C for 2
containing RPMI-1640 medium in the absence or pres- min) were carried out, followed by an additional 10-
ence of various amounts of VLDL. Subsequently, an minute extension at 728C. In preliminary experiments,
aliquot of THP-1 cells (2 3 105) was added to each dish, 25 to 30 cycles of PCR amplification were used, and 30
and cells were further incubated for one hour. At the cycles provided optimum results. The products of PCR
end of incubation, the nonadherent monocytes were were separated by 1.8% agarose gel (containing ethidium
rinsed, and the attached cells were fixed with 1% glutar- bromide) electrophoresis and visualized under ultravio-
aldehyde. The number of attached THP-1 was deter- let light using a gel documentation system (Bio-Rad Gel
mined by counting 8 to 30 random fields per dish under Doc1000). Glyceraldehyde 3-phosphate dehydrogenase
light microscopy (3100 magnification). We found that (GAPDH) was used as an internal standard to verify
counting nine fields per dish consistently provided data equal PCR product loading for each experiment. After
similar to that obtained with a larger number of fields. the RT-PCR reaction, the MCP-1 signal was normalized
For subsequent adhesion experiments, nine random by comparison with the GAPDH signal from the same
fields per dish were used to determine the number of sample. The values are expressed as a ratio of MCP-1
attached THP-1. to GAPDH.
Determination of VCAM-1 and ICAM-1 proteins inDetermination of monocyte chemoattractant protein-1
levels in culture media mesangial cells
Vascular cell adhesion molecule-1 and ICAM-1 proteinThe amount of MCP-1 protein secreted into the cul-
ture medium was determined by solid-phase immunoas- levels were measured by enzyme-linked immunosorbent
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assay (ELISA) [40]. In brief, mesangial cells were cultured chlorate [DiI or DiC18(3)] and obtained from Molecular
in 96-well plates. Cells were incubated in the absence or Probes (Eugene, OR, USA) [47–49]. In brief, VLDL
presence of different concentrations of VLDL for six was mixed with lipoprotein depleted FBS in a 1:5 ratio
hours at 378C. After incubation, the cells were washed by weight. One microgram of DiI was added per 25 mg
with PBS and then fixed with 0.1% glutaraldehyde for VLDL protein. The solution was mixed and then incu-
one hour at 48C. Cells were then washed with PBS and bated for 18 hours at 378C. After incubation, DiI-VLDL
allowed to dry overnight followed by blocking with 10% was reisolated by sequential ultracentrifugation. DiI-
powdered milk in PBS. The cells were then incubated VLDL was filter sterilized, and the protein concentration
with either anti–VCAM-1 (1:500) or anti–ICAM-1 (1:500) and specific activity (ng DiI per mg VLDL protein) were
antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, determined.
CA, USA). After incubation for one hour at room tem- For the experiments, mesangial cells were incubated
perature, cells were washed with 10% powdered milk in the presence or absence of DiI-VLDL (5 to 50 mg/mL
and were incubated with rabbit antigoat IgG-horseradish DiI-VLDL) for six hours at 378C. After incubation, cells
peroxidase conjugate antibodies (1:1000; Bio-Rad) for were washed thoroughly with 1% bovine serum albumin
an additional one hour. After washing, the ELISA was (BSA) in PBS, followed by three additional washes with
developed for one hour at room temperature using a PBS. Fluorescent label was extracted by adding isopro-
phenylenediamine substrate in citrate buffer containing panol and incubating for 15 minutes on an orbital shaker
0.006% hydrogen peroxide. Absorbency was measured at room temperature. The fluorescence of the isopropa-
at 450 nm using a MRX Microplate Reader (Dynex nol extract was assayed using a Fluorolite 1000 fluorom-
Technologies, Chantilly, VA, USA). eter (Dynex Technologies) with an excitation/emission
of 531/580 nm.Determination of protein kinase C activity
Cell extracts were prepared according to Johnson, Identification of foam cells with Oil Red O
Edwards, and Newton [45]. All steps for the prepara- Mesangial cells were cultured for six hours in 35 mm
tion of cell extracts were performed at 48C. Mesangial dishes containing RPMI-1640 medium in the absence or
cells were harvested in PBS and pelleted by centrifuga- presence of various amounts of VLDL. Subsequently,
tion. Cells were sonicated in 0.2 mL lysis buffer [50 an aliquot of THP-1 cells (2 3 105) was added to each
mmol/L HEPES, pH 7.5, 0.2% (wt/vol) Triton X-100, dish, and cells were further incubated for one hour. At
1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L DTT, 85 the end of incubation, the nonadherent monocytes were
mmol/L leupeptin, 2 mmol/L benzamidine, 0.4 mmol/L
rinsed. Fresh media containing VLDL (100 to 300 mg/mL)
phenylmethylsulfonyl fluoride] followed by centrifuga-
were added, and cells were incubated for an additionaltion at 100,000 3 g for 20 minutes (TLA 120.2; Beckman,
24 hours. After incubation, cells were washed with PBSPalo Alto, CA, USA) to obtain a detergent-soluble frac-
and stained with Oil Red O (ORO) for 10 minutes andtion (supernatant). A 5 mL aliquot of this fraction was
counterstained with hematoxylin for 6 minutes. Cellsused for determination of protein kinase C (PKC) activity.
were examined under a light microscope (Bx50-PM20;Protein kinase C activity toward a synthetic peptide
Olympus Optical Co., Ltd., Tokyo, Japan). Macrophages(Ac-FKKSFKL-NH2) was determined as described by
with 10 or more lipid droplets were identified as foamEdwards and Newton [46]. Standard reaction mixture
cells [50].contained 50 mmol/L peptide substrate in 20 mmol/L
HEPES (pH 7.5), 1 mmol/L DTT, 100 mmol/L [g-32P]ATP Statistical analysis
(approximately 1500 cpm/pmol), 5 mmol/L MgCl2, and
Student t-test was used for statistical analysis between0.5 mmol/L CaCl2 and sonicated dispersions of brain
two groups. The level of statistical significance was P ,phosphatidylserine (140 mmol/L) and diacylglycerol (3.8
0.05.mmol/L). After eight minutes of incubation at 308C, the
reaction was terminated by spotting an aliquot of the
reaction mixture onto Whatman P81 ion-exchange chro- RESULTS
matography paper, followed by four washes with 0.4%
Effect of VLDL on monocyte adhesion to(vol/vol) phosphoric acid and a 95% ethanol rinse. Ra-
mesangial cellsdioactivity (32P) incorporation into the peptide substrate
Mesangial cells were preincubated with various amountswas determined by liquid scintillation counting.
of VLDL for six hours. THP-1 monocytes were then
Determination of the uptake of DiI-very low-density added to cultured mesangial cells, and the incubation
lipoprotein by mesangial cells was continued for an additional hour. At the end of
incubation, the number of monocytes attached to mesan-Very low-density lipoprotein was labeled with 1,19-
dioctadecyl-3,3,39,39-tetramethylindocarbocyanine per- gial cells was estimated, and the results are depicted in
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Fig. 2. Effect of monocyte chemoattractant protein-1 (MCP-1) antibodyFig. 1. Effect of very low density lipoprotein (VLDL) on Tamm-Hors-
on VLDL-induced THP-1 adhesion to rat mesangial cells. Mesangialfall protein-1 (THP-1) adhesion to rat mesangial cells. Mesangial cells
cells were incubated in the presence (1) or absence (2) of VLDL forwere treated for six hours in the presence or absence of VLDL, followed
six hours, followed by a one-hour incubation with 2 3 105 THP-1 perby a one-hour incubation with 2 3 105 THP-1 per milliliter. The cells
milliliter. Thirty minutes prior to the addition of THP-1, 0.5 mg/mLwere then washed vigorously and fixed with 1% glutaraldehyde. Nine
anti-MCP-1 antibody (Ab) was added to the appropriate tissue culturerandom 1.02 mm2 fields per dish were hand counted to determine the
dishes. After the experiment, cells were washed vigorously and fixednumber of adhering THP-1. Control cells were incubated in the absence
with 1% glutaraldehyde. Nine random fields per dish were hand countedof VLDL. The results shown are the mean 6 SD from four independent
to determine the number of adhering THP-1. Control cells were incu-experiments. **P , 0.005 relative to control.
bated in the absence of VLDL. Results are depicted as the mean 6
SD from four separate experiments. **P , 0.005 relative to control.
Figure 1. VLDL treatment caused an increase in the
Effect of VLDL on MCP-1 mRNA levels innumber of THP-1 cells adhering to mesangial cells in a
mesangial cellsdose-dependent manner. VLDL treatment (75 to 200
mg/mL) resulted in a 252 to 426% stimulation of THP-1 An increase in MCP-1 protein secretion by VLDL-
treated cells might be a result of changes in the expres-adhesion. Lower levels of VLDL (50 mg/mL) had no
sion of MCP-1 mRNA in these cells. The effect of VLDLsignificant effect on THP-1 adhesion. A similar stimula-
on the expression of MCP-1 mRNA was examined bytion was observed when mesangial cells were preincu-
RT-PCR. To determine whether VLDL affected the lev-bated with VLDL for 12 hours (data not shown). To
els of MCP-1 mRNA, cells were preincubated withdetermine whether anti–MCP-1 antibodies could block
VLDL (100 to 300 mg/mL) for six hours, and total cellularthis stimulatory effect, mesangial cells were preincubated
RNA was extracted. As shown in Figure 4, the levels ofwith VLDL followed by the addition of anti–MCP-1
MCP-1 mRNA were significantly elevated in mesangialantibodies. As shown in Figure 2, antibody treatment
cells treated with VLDL. After cells were treated with(0.5 mg/mL) completely abolished the stimulative effect
VLDL at concentrations of 100, 200, and 300 mg/mL,of VLDL on THP-1 adhesion to mesangial cells. These
the ratio of MCP-1 to GAPDH was increased from 0.68results suggest that the production of MCP-1 might be
(0 mg/mL VLDL) to 0.77, 0.84, and 1.04, respectively,up-regulated in VLDL-treated mesangial cells.
reflecting a significant increase in levels of mRNA. These
results indicate that increased secretion of MCP-1 byEffect of VLDL on MCP-1 secretion
mesangial cells was a result of increased levels of MCP-1
The effect of VLDL on MCP-1 secretion by mesangial mRNA in VLDL-treated cells. The disparity between
cells was examined by solid-phase immunoassay. As de- the expression of MCP-1 protein (Fig. 3) and mRNA
picted in Figure 3, VLDL treatment (100 to 300 mg/mL) (Fig. 4) found in control cells (0 mg/mL VLDL) might
significantly stimulated the release of MCP-1 (54 to 285 be due to a difference in sensitivities of the respective
ng/well) by mesangial cells. Mesangial cells incubated in assays or due to differential regulation of MCP-1 protein
the absence of VLDL secreted a low, basal level of expression and MCP-1 mRNA expression. Time-course
MCP-1 (12 ng/well). Lipopolysaccharide has been shown experiments of MCP-1 mRNA expression in mesangial
to induce MCP-1 expression in many cell types, including cells were also performed. Cells were incubated in the
mesangial cells [28]. In our study, the incubation of mes- presence or absence of VLDL (100 mg/mL) for various
angial cells with lipopolysaccharide (0.1 to 10 mg/mL) time periods, and total cellular RNA was extracted fol-
for six hours resulted in a significant elevation (136 to lowed by RT-PCR. As shown in Figure 5, MCP-1 mRNA
214% of control) in the levels of MCP-1 secreted by expression in cells treated with VLDL (100 mg/mL)
reached a maximum at six hours of incubation.mesangial cells (data not shown).
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Fig. 3. Effect of VLDL on rat mesangial cell MCP-1 secretion. Mesan-
gial cells were treated for six hours in the presence or absence of
Fig. 4. Effect of VLDL on MCP-1 mRNA. Mesangial cells were treateddifferent concentrations of VLDL. Aliquots of culture media were
with different concentrations of VLDL for six hours. After incubation,taken, and MCP-1 protein was determined by Western Immunoblotting.
total RNA was extracted, and RT-PCR was performed as describedThe upper panel shows a typical Western immunoblot. Results are
in the Methods section. Parallel PCR reactions were performed fordepicted as the mean 6 SD of four independent experiments. *P ,
GAPDH. PCR products were separated by 1.8% agarose gel electro-0.05; **P , 0.005 relative to 0 mg/mL VLDL.
phoresis. The upper panel shows a typical agarose gel visualized using
ethidium bromide. Lane 1, 0 mg/mL VLDL; lane 2, 100 mg/mL VLDL;
lane 3, 200 mg/mL VLDL; lane 4, 300 mg/mL VLDL. Results are depicted
as the mean 6 SD from four independent experiments. *P , 0.05; **P ,
Effect of VLDL on VCAM-1 and ICAM-1 protein 0.025 relative to 0 mg/mL VLDL.
levels in mesangial cells
To investigate whether VLDL could also stimulate
VCAM-1 and ICAM-1 protein levels in mesangial cells, VLDL at equivalent lipid concentrations (Fig. 1). This
ELISA was performed. After VLDL treatment (100 to suggests that the apolipoprotein component of VLDL
300 mg/mL), neither VCAM-1 nor ICAM-1 concentra- may be required to obtain the full stimulatory effect on
tions were significantly elevated in the VLDL-treated monocyte adhesion. Liposome treatment also stimulated
mesangial cells (Fig. 6). Both control and VLDL-treated MCP-1 secretion by mesangial cells (data not shown).
mesangial cells secreted a low level of VCAM-1 (25 to
Role of PKC in VLDL-induced monocyte adhesion28 ng/mL) and ICAM-1 (29 to 32 ng/mL).
Protein kinase C (PKC) has been indicated to play a
Effect of VLDL lipids on monocyte adhesion role in the activation of the MCP-1 gene in endothelial
To identify which components of the VLDL particles cells [51], as well as in mesangial cells [36]. To investigate
were responsible for the induction of MCP-1 expression whether PKC was involved in the VLDL-induced MCP-1
in mesangial cells, the effect of VLDL lipids on monocyte protein expression, mesangial cells were preincubated
adhesion to mesangial cells was investigated. Mesangial with VLDL in the presence of staurosporine, a protein
cells were preincubated with various amounts of VLDL- kinase inhibitor, followed by a monocyte adhesion exper-
like liposomes for six hours. THP-1 monocytes were then iment as described earlier here. As shown in Figure 8,
added to cultured mesangial cells, and the incubation staurosporine (1 nmol/L) completely blocked VLDL-
was continued for an additional one hour. At the end induced THP-1 adhesion. These results suggest that PKC
of incubation, the number of monocytes attached to mes- may play a key regulatory role in VLDL-induced MCP-1
angial cells was estimated, and the results are depicted in secretion by mesangial cells. The role of PKC was further
Figure 7. At concentrations of 226 nmol cholesterol/mL examined by measuring PKC activity in VLDL-treated
(equivalent to 100 mg protein/mL VLDL) and 452 nmol mesangial cells. As shown in Table 1, VLDL treatment
cholesterol/mL (equivalent to 200 mg protein/mL VLDL), significantly stimulated the PKC activity in mesangial
adhesion of monocytes to cultured mesangial cells was cells. VLDL (100 mg protein/mL) was able to increase
significantly stimulated 152 and 222%, respectively. As PKC activity to 130% of the control. This stimulatory
shown in Figure 7, anti–MCP-1 antibody was able to block effect was abolished by staurosporine (1 nmol/L).
liposome-induced monocyte adhesion completely. Al-
Role of calcium in VLDL-induced monocyte adhesionthough the lipid component of VLDL alone was capable
of stimulating monocyte adhesion to mesangial cells, lipo- To determine the contribution of calcium in VLDL-
induced PKC activation and MCP-1 expression, mesan-some treatment had a lesser effect when compared with
Lynn et al: VLDL stimulates MCP-1 expression1478
Fig. 5. Time course of MCP-1 mRNA expres-
sion in mesangial cells. Mesangial cells were
incubated in the presence or absence of VLDL
(100 mg/mL) for various time periods, and to-
tal cellular RNA was extracted followed by
RT-PCR as described in the Methods section.
Parallel PCR reactions were performed for
GAPDH. PCR products were separated by
1.8% agarose gel electrophoresis. This figure
depicts the results from a typical time course
experiment visualized using ethidium bromide.
(data not shown). Similar results were obtained when
another calcium channel blocker, nicardipine, was used.
Role of VLDL in foam cell formation
Foam cell formation and lipid accumulation are key
characteristics in the pathogenesis of focal glomerulo-
sclerosis. We first examined the accumulation of lipids
in mesangial cells. DiI-labeled VLDL (5 to 50 mg/mL)
was incorporated into mesangial cells in a dose-depen-
dent manner (Fig. 9). This result suggests that VLDL
may be able to contribute to excess lipid deposition and
foam cell formation. To determine this hypothesis, mes-
angial cells and attached THP-1 cells were cultured in
the absence or presence of VLDL (100 to 300 mg/mL)
for 24 hours as described previously in this article. After
incubation, cells were stained with ORO and counter-
stained with hematoxylin. Mesangial cells alone and mes-
angial cells coincubated with THP-1 showed no lipid
accumulation in the absence of VLDL, as seen by the
lack of ORO stain (Fig. 10 A, B). In contrast, there was
an obvious accumulation of lipids in both mesangial cells
and attached THP-1 cells when treated with 200 mg/mL
VLDL, as seen by ORO stain (Fig. 10C). THP-1 cells
accumulated large amounts of lipid to form foam cell-
like cells, and numerous lipid droplets also accumulated
in mesangial cells (Fig. 10C).
DISCUSSION
Hyperlipidemia is regarded as one of the contributingFig. 6. Effect of VLDL on mesangial VCAM-1 (A) and ICAM-1 (B)
protein. VCAM-1 and ICAM-1 protein levels in mesangial cells were factors in the development of focal glomerulosclerosis [4,
determined by ELISA. Mesangial cells were incubated with different 6, 7, 10, 53–57]. Glomerular lipid deposition is associatedconcentrations of VLDL for six hours at 378C. ELISA was performed
with an increased infiltration of monocytes and the for-as described in the Methods section. Absorbency was measured at 450
nm. Control cells were incubated in the absence of VLDL. Results are mation of foam cells in the affected glomeruli [8, 9, 20,
depicted as the mean 6 SD from six independent experiments. 26, 42, 50, 58–60]. Glomerular lipid deposition can pose
a direct injury to the glomerular mesangium, as well
as alter the function of mesangial cells. Similar to the
pathogenesis of atherosclerosis, the recruitment of mono-gial cells were treated with diltiazem (Sigma Chemical
cytes is an early event in glomerulosclerosis [8, 9]. In-Co.), an l-type calcium channel blocker [52]. As depicted
creased expression of MCP-1, characteristic of monocytein Figure 8, diltiazem (100 nmol/L) was able to block
infiltration, has been detected in arterial walls of animalVLDL-induced monocyte adhesion completely. These
models of atherosclerosis [61] and in human atheroma-results suggest that the activation of PKC by VLDL
tous plaques [62, 63]. The elevated expression of thisis calcium dependent. In addition, diltiazem treatment
completely blocked VLDL-induced MCP-1 secretion chemoattractant protein in glomeruli was seen in several
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Fig. 7. Effect of MCP-1 antibody on liposome-
induced THP-1 adhesion to RMC. Mesangial
cells were incubated in the presence or absence
of 226 nmol free cholesterol (FC)/mL (equiva-
lent to the amount of lipid found in 100 mg/mL
VLDL) or 452 nmol FC/mL liposomes for six
hours, followed by a one-hour incubation with
2 3 105 THP-1/mL. Thirty minutes prior to
the addition of THP-1, some mesangial cells
were pretreated with 0.5 mg/mL anti-MCP-1
antibody (Ab). After the experiment, cells
were washed vigorously and fixed with 1%
glutaraldehyde. Nine random 1.02 mm2 fields
per dish were hand counted to determine the
number of adhering THP-1. Control cells were
incubated in the absence of liposomes. Results
are depicted as the mean 6 SD from four
independent experiments. *P , 0.05; **P ,
0.005 relative to control.
Fig. 8. Effect of staurosporine/calcium chan-
nel blockers on VLDL-induced THP-1 adhe-
sion to rat mesangial cells. Mesangial cells
were incubated for six hours at 378C in the
presence or absence of VLDL, staurosporine,
or calcium channel blocker, followed by a one-
hour incubation with 2 3 105 THP-1/mL. After
the experiment, cells were washed vigorously
and fixed with 1% glutaraldehyde. Nine ran-
dom 1.02 mm2 fields per dish were hand
counted to determine the number of adhering
THP-1. Control cells were incubated in the
absence of VLDL. Results are depicted as the
mean 6 SD of four independent experiments.
**P , 0.005 relative to control.
Table 1. Effect of VLDL on PKC activity One of the initiating events in the pathogenesis of
focal glomerulosclerosis is the infiltration of monocytesPKC activity
Treatment pmol/min/mg protein into glomeruli, where they become foam cells following
Control 853650 the uptake of massive amounts of lipid [59, 60, 65]. The
100 mg/mL VLDL 1110663a presence of foam cells in the mesangial region of the kid-
100 mg/mL VLDL 1 1 nmol/L staurosporine 977689
ney was demonstrated in patients with familial type III
Cells were treated for 6 hours in the presence or absence of very low density hyperlipoproteinemia associated with diabetes mellituslipoprotein (VLDL). After incubation, the cells were harvested and protein
kinase C (PKC) activity measured as described in the Methods section. Control or nephrotic syndrome [19–21]. Modified LDL was shown
cells were incubated in the absence of VLDL/staurosporine. The results shown in vitro to induce foam cell formation in monocyte-derivedare the mean 6 standard deviation from three separate experiments.
a P , 0.01 relative to control macrophages [59]. Oxidized LDL was able to cause the
accumulation of large amount of lipids in mouse perito-
neal macrophages [59]. We recently reported that lipo-
protein-X, an abnormal lipoprotein found in patientsrenal diseases [33, 36–39, 64]. In this study, we clearly
with familial lecithin:cholesterol acyltransferase (LCAT)demonstrate that VLDL can stimulate MCP-1 produc-
deficiency, induced foam cell formation in rat peritonealtion in cultured rat mesangial cells. Such stimulatory
macrophages [50]. In the present study, we demonstrateeffect results in an increased adhesion of THP-1 mono-
that upon adhesion to mesangial cells, THP-1 cells cancytic cells to mesangial cells. However, neither VCAM-1
become foam cells after incubation with VLDL. Ournor ICAM-1 protein levels were significantly altered in
results suggest that VLDL-induced monocyte adhesionVLDL-treated cells. VLDL-induced MCP-1 expression
to glomeruli is mediated by MCP-1 expressed by mesan-and consequent adhesion of THP-1 monocytic cells can
gial cells. The attached monocytes can uptake massivebe attenuated by inhibiting PKC activity or by a calcium
channel blocker. amount of lipids (lipoproteins) to form foam cells. Foam
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Fig. 9. Uptake of DiI-VLDL by rat mesangial
cells. Mesangial cells were incubated in the pres-
ence or absence of VLDL labeled with the fluo-
rescent marker DiI (1,19-dioctadecyl-3,3,39,39-
tetramethylindocarbocyanine perchlorate) for
six hours at 378C. Cells were then washed
vigorously and DiI was extracted with isopro-
panol. DiI was assayed using a fluorometer
(Fluorolite 1000; Dynex Technologies) with
an excitation/emission of 531/580 nm. VLDL
uptake was calculated from the specific activ-
ity (ng DiI incorporated per mg VLDL pro-
tein) of DiI-VLDL. Results are depicted as
the mean 6 SD from four independent experi-
ments. **P , 0.005 relative to 0 mg/mL VLDL.
Fig. 10. Effect of VLDL on foam cell formation. Mesangial cells were treated for six hours in the absence or presence of VLDL (200 mg/mL),
followed by a one-hour incubation with 2 3 105 THP-1/mL. Cells were then washed and incubated for another 24 hours in the absence or presence
of VLDL (200 mg/mL). After incubation, cells were stained with ORO and hematoxylin. Cells were examined under a light microscope (3400
magnification). (A) Mesangial cells incubated in the absence of VLDL. The large arrow indicates a mesangial cell. (B) Co-cultured mesangial cells
and attached THP-1 cells incubated in the absence of VLDL. The large arrow indicates a mesangial cell and small arrows indicate THP-1 cells.
(C) Co-cultured mesangial cells and attached THP-1 cells incubated with VLDL (200 mg/mL). The large arrow indicates a mesangial cell filled
with lipid droplets, and the small arrow indicates foam cells derived from THP-1 cells.
cells are able to secrete a variety of cytokines that may cells [24]. This process was mediated by the LDL recep-
tor pathway, as well as the VLDL receptor pathwaystimulate further recruitment of monocytes, cell prolifer-
ation, remodeling of the extracellular matrix, and ulti- [24]. In the present study, we demonstrate that VLDL-
induced expression of MCP-1 in mesangial cells is accom-mately the pathogenesis of focal glomerulosclerosis.
Recent evidence also suggests that besides the induc- panied by increased uptake of VLDL by these cells.
Results obtained indicate that VLDL could cause lipidtion of foam cell formation from infiltrated monocytes,
foam cells can also originate from mesangial cells [23, 24]. accumulation (DiI-VLDL) in mesangial cells. The accu-
mulation of VLDL lipids in mesangial cells was furtherMesangial cells can uptake massive amounts of lipopro-
teins via LDL receptor, scavenger receptor, as well as confirmed after cells were stained with ORO. VLDL parti-
cles are triglyceride-rich lipoproteins that consist of sur-VLDL receptor, which can lead to intracellular accumu-
lation of lipids [24, 66–68]. The accumulation of lipids in face components (cholesterol, phospholipids, apoB-100,
apoE, and apoCs) and core lipids (triglycerides andmesangial cells may alter the function and the metabolic
processes of these cells. It was shown recently that human cholesteryl esters). Our results indicate that the lipid
components of VLDL are capable of stimulating MCP-1b-VLDL could induce foam cell formation in mesangial
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expression in mesangial cells, although to a lesser extent The mechanism by which VLDL regulates calcium chan-
nels also remains to be investigated.when compared with native VLDL.
The VLDL-mediated stimulation of MCP-1 expres-A recent study has shown that mildly oxidized LDL,
sion may also involve the transcription factor, nuclearbut not native LDL, stimulated both VCAM-1 and
factor-kB (NF-kB). Analysis of the promoter region ofICAM-1 expression in human mesangial cells [40]. In
the MCP-1 gene has revealed several putative bindingour study, VLDL had no significant effect on VCAM-1 or
sites for transcription-activator factors, including NF-kB.ICAM-1 protein levels in rat mesangial cells. However,
It has been proposed that activated NF-kB binds to theVLDL-treated mesangial cells expressed elevated levels
promoter region of the human MCP-1 gene and stimu-of MCP-1. These results suggest that VLDL-mediated
lates the expression of this chemoattractant protein [64,MCP-1 expression by mesangial cells may contribute
72, 73]. PKC has been shown to be able to activateconsiderably to the enhanced monocyte adhesion seen
NF-kB [64, 74]. Hence, VLDL-induced PKC activity mayin this study.
stimulate the activation of NF-kB, resulting in the subse-In the present study, we have further investigated the
quent stimulation of MCP-1 expression.possible mechanisms by which VLDL stimulates MCP-1
Several factors can contribute to the pathogenesis ofproduction in mesangial cells. MCP-1 gene expression
focal glomerulosclerosis, including hemodynamic alter-in mesangial cells was stimulated by glucose in diabetic
ations, hypertension, coagulation factors, or genetic fac-nephropathy via a PKC-mediated signaling pathway [36].
tors, as well as hyperlipidemia [2–5]. In summary, ourThe glucose-induced elevation of MCP-1 mRNA was
study clearly demonstrates that VLDL stimulates thesignificantly inhibited by calphostin C, a PKC inhibitor,
expression of MCP-1 in mesangial cells, followed by in-in human mesangial cells [36]. In addition, it was shown
creased adhesion of monocytes to mesangial cells. Suchin human endothelial cells that PKC activation might be
stimulation may be mediated partially through a calcium-essential in the cyclic stretch-induced secretion and gene
dependent PKC signaling pathway. Our results provideexpression of MCP-1 [51]. Calphostin C was shown to
one of the mechanisms of VLDL-induced focal glomeru-completely block the stretch-induced elevation of MCP-1
losclerosis: the stimulation of monocyte recruitment, themRNA levels [51]. In this study, we have found that a
subsequent formation of foam cells, as well as lipid accu-PKC-mediated mechanism may also be responsible for
mulation in affected glomeruli, via a mechanism involv-the stimulatory effect of VLDL on MCP-1 secretion by
ing MCP-1. Future studies are needed to investigate themesangial cells and the consequent monocyte adhesion.
role of other risk factors in the initiation and progressionThis stimulatory effect was calcium dependent and was
of focal glomerulosclerosis.abolished by the addition of staurosporine, an inhibitor
of PKC. We further demonstrated that the PKC-medi-
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APPENDIXcalcium antagonists were found to be antiatherogenic in
Abbreviations used in this article are: DiI, 1,19-3,3,39,39-tetramethyl-experimental rabbits fed a cholesterol-rich diet [69]. In
indocarbocyanine perchlorate; DTT, dithiothreitol; EDTA, ethylene-addition, increased calcium levels were observed in en- diaminetetraacetic acid; EGTA, egtazic acid; FBS, fetal bovine serum;
dothelial cells treated with LDL [70]. Results from the GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HRP, horseradish
peroxidase; ICAM-1, intercellular adhesion molecule-1; LDL, low den-present study suggest that VLDL may alter the calcium
sity lipoprotein; MCP-1, monocyte chemoattractant protein-1; NF-kB,influx in mesangial cells, which in turn activates mem- nuclear factor-kB; ORO, Oil Red O; PKC, protein kinase C; RT-PCR,
brane-bound PKC. Hence, VLDL-stimulated expression reverse transcription-polymerase chain reaction; THP-1, Tamm-Horsfall
protein-1; VCAM-1, vascular cell adhesion molecule-1; VLDL, veryof MCP-1 in mesangial cells may be partially mediated
low density lipoprotein.via a PKC/calcium signaling pathway. However, it re-
mains to be investigated whether VLDL treatment re-
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